주산기 감염증 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 감염증 유형별, 치료법별, 진단별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Perinatal Infections Market, valued at USD 1.6 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 2.18 Billion by 2030. The Global Perinatal Infections Market focuses on diagnostic and therapeutic solutions for infections caused by viruses or bacteria transmitted from a mother to her fetus during gestation or childbirth. Market expansion is substantially driven by the increasing global prevalence of these infections, alongside rising healthcare expenditure and heightened public awareness concerning maternal and child health. Further growth is supported by continuous technological advancements in diagnostic methodologies and treatment modalities, facilitating earlier detection and more effective interventions.

Key Market Drivers

The Global Perinatal Infections Market is significantly shaped by sustained technological advancements in diagnostics and treatment. Innovations in diagnostic platforms are continuously enhancing the precision and accessibility of early detection for perinatal infections. This includes the development of non-invasive prenatal tests, which allow for screening of complex fetal genetic conditions with reduced risk. For instance, according to Natera, in August 2025, their Fetal Focus test, a noninvasive prenatal test for inherited conditions, was launched, supported by data from a clinical trial that initiated in 2023 and had enrolled approximately 1,300 participants. These diagnostic breakthroughs enable earlier and more accurate identification of infections, facilitating timely intervention and improving outcomes for both mother and child.

Key Market Challenges

The scarcity of adequately skilled healthcare professionals capable of providing accurate diagnosis and comprehensive treatment for complex perinatal conditions significantly impedes the growth of the Global Perinatal Infections Market. This shortage directly limits the effective deployment and utilization of innovative diagnostic technologies and therapeutic solutions. When there are insufficient trained personnel, particularly those specializing in infectious diseases, the ability to promptly and accurately identify perinatal infections is compromised. This often leads to delayed treatment initiation, reduced efficacy of available interventions, and poorer maternal and neonatal outcomes.

Key Market Trends

The growing adoption of personalized medicine approaches represents a pivotal trend reshaping the Global Perinatal Infections Market by moving beyond standardized treatments to highly individualized care. This trend emphasizes tailoring diagnostic and therapeutic interventions based on a mother's unique genetic profile, microbial resistance patterns, and immune response, aiming to optimize outcomes for both mother and child. Such customization drives demand for advanced molecular diagnostics capable of identifying specific pathogens and host genetic predispositions with high precision. According to the Personalized Medicine Coalition, the FDA approved 18 new personalized medicines in 2024, constituting 38% of all newly approved therapeutic molecular entities across various treatment areas. Companies are increasingly collaborating in this space; Roche and Janssen Biotech Inc. joined forces in February 2023 to develop personalized and targeted therapies alongside companion diagnostics, signaling a strategic focus on this tailored medical paradigm.

Key Market Players

• Merck KGaA
• Beckman Coulter Inc.
• Bio-Rad Laboratories, Inc
• Hologic Inc.
• Gilead Sciences, Inc.
• Emcure Pharmaceuticals Limited.
• Cipla Inc.
• Bausch Health Companies Inc
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Perinatal Infections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Perinatal Infections Market, By Infection Type:

• Cytomegalovirus Infection
• Enterovirus Infection
• Genital Herpes
• Gonorrhoea
• Human Immunodeficiency Virus
• Listeriosis Lymphocytic Choriomeningitis Virus
• Rubella
• Syphilis
• Varicella
• Others

Perinatal Infections Market, By Treatment:

• Antibiotics
• Antiviral
• Antiretroviral
• Others

Perinatal Infections Market, By Diagnosis:

• Maternal Test
• Neonatal Test
• Others

Perinatal Infections Market, By End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Perinatal Infections Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Perinatal Infections Market.

Available Customizations:

Global Perinatal Infections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Perinatal Infections Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella, Others)
  • 5.2.2. By Treatment (Antibiotics, Antiviral, Antiretroviral, Others)
  • 5.2.3. By Diagnosis (Maternal Test, Neonatal Test, Others)
  • 5.2.4. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Perinatal Infections Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Infection Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Perinatal Infections Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Infection Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Diagnosis
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Perinatal Infections Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Infection Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Diagnosis
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Perinatal Infections Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Infection Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Diagnosis
      • 6.3.3.2.4. By End user

7. Europe Perinatal Infections Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Infection Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Perinatal Infections Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Infection Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Diagnosis
      • 7.3.1.2.4. By End user
  • 7.3.2. France Perinatal Infections Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Infection Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Diagnosis
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Perinatal Infections Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Infection Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Diagnosis
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Perinatal Infections Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Infection Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Diagnosis
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Perinatal Infections Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Infection Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Diagnosis
      • 7.3.5.2.4. By End user

8. Asia Pacific Perinatal Infections Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Infection Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Perinatal Infections Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Infection Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Diagnosis
      • 8.3.1.2.4. By End user
  • 8.3.2. India Perinatal Infections Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Infection Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Diagnosis
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Perinatal Infections Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Infection Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Diagnosis
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Perinatal Infections Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Infection Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Diagnosis
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Perinatal Infections Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Infection Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Diagnosis
      • 8.3.5.2.4. By End user

9. Middle East & Africa Perinatal Infections Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Infection Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Perinatal Infections Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Infection Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Diagnosis
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Perinatal Infections Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Infection Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Diagnosis
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Perinatal Infections Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Infection Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Diagnosis
      • 9.3.3.2.4. By End user

10. South America Perinatal Infections Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Infection Type
  • 10.2.2. By Treatment
  • 10.2.3. By Diagnosis
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Perinatal Infections Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Infection Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Diagnosis
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Perinatal Infections Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Infection Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Diagnosis
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Perinatal Infections Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Infection Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Diagnosis
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Perinatal Infections Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Beckman Coulter Inc.
• 15.3. Bio-Rad Laboratories, Inc
• 15.4. Hologic Inc.
• 15.5. Gilead Sciences, Inc.
• 15.6. Emcure Pharmaceuticals Limited.
• 15.7. Cipla Inc.
• 15.8. Bausch Health Companies Inc
• 15.9. Johnson & Johnson
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer